nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Procarbazine—brain cancer	0.723	0.803	CbGbCtD
Deferoxamine—XDH—Carboplatin—brain cancer	0.177	0.197	CbGbCtD
Deferoxamine—XDH—Effects of Nitric Oxide—MB—brain cancer	0.00448	0.861	CbGpPWpGaD
Deferoxamine—Lung infiltration—Lomustine—brain cancer	0.00417	0.0437	CcSEcCtD
Deferoxamine—Blindness—Lomustine—brain cancer	0.00353	0.037	CcSEcCtD
Deferoxamine—Tonic-clonic seizures—Carmustine—brain cancer	0.00288	0.0302	CcSEcCtD
Deferoxamine—Lung infiltration—Hydroxyurea—brain cancer	0.00205	0.0215	CcSEcCtD
Deferoxamine—Optic neuritis—Procarbazine—brain cancer	0.00202	0.0212	CcSEcCtD
Deferoxamine—Lung infiltration—Carmustine—brain cancer	0.00166	0.0174	CcSEcCtD
Deferoxamine—Grand mal convulsion—Carmustine—brain cancer	0.00163	0.0171	CcSEcCtD
Deferoxamine—Visual disturbance—Lomustine—brain cancer	0.0015	0.0157	CcSEcCtD
Deferoxamine—Induration—Etoposide—brain cancer	0.00134	0.0141	CcSEcCtD
Deferoxamine—Transaminases increased—Carmustine—brain cancer	0.00128	0.0134	CcSEcCtD
Deferoxamine—Visual acuity reduced—Temozolomide—brain cancer	0.00126	0.0132	CcSEcCtD
Deferoxamine—Aphasia—Carmustine—brain cancer	0.0012	0.0126	CcSEcCtD
Deferoxamine—Neuropathy—Procarbazine—brain cancer	0.00117	0.0122	CcSEcCtD
Deferoxamine—Aphasia—Temozolomide—brain cancer	0.00116	0.0121	CcSEcCtD
Deferoxamine—Renal failure—Lomustine—brain cancer	0.00108	0.0113	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Procarbazine—brain cancer	0.00103	0.0108	CcSEcCtD
Deferoxamine—Scotoma—Carmustine—brain cancer	0.00102	0.0107	CcSEcCtD
Deferoxamine—Scotoma—Temozolomide—brain cancer	0.000988	0.0104	CcSEcCtD
Deferoxamine—Optic neuritis—Etoposide—brain cancer	0.000976	0.0102	CcSEcCtD
Deferoxamine—Injection site pain—Carmustine—brain cancer	0.000951	0.00997	CcSEcCtD
Deferoxamine—Visual impairment—Lomustine—brain cancer	0.000946	0.00992	CcSEcCtD
Deferoxamine—Cyanosis—Etoposide—brain cancer	0.000848	0.00889	CcSEcCtD
Deferoxamine—Infection—Carboplatin—brain cancer	0.000792	0.0083	CcSEcCtD
Deferoxamine—Injection site reaction—Carmustine—brain cancer	0.000772	0.00809	CcSEcCtD
Deferoxamine—Eosinophilia—Procarbazine—brain cancer	0.000771	0.00808	CcSEcCtD
Deferoxamine—Leukopenia—Lomustine—brain cancer	0.000765	0.00802	CcSEcCtD
Deferoxamine—Renal failure acute—Hydroxyurea—brain cancer	0.000755	0.00792	CcSEcCtD
Deferoxamine—Neuropathy—Carmustine—brain cancer	0.000729	0.00764	CcSEcCtD
Deferoxamine—Neuropathy—Temozolomide—brain cancer	0.000705	0.00739	CcSEcCtD
Deferoxamine—Infection—Lomustine—brain cancer	0.000693	0.00727	CcSEcCtD
Deferoxamine—Thrombocytopenia—Lomustine—brain cancer	0.000683	0.00716	CcSEcCtD
Deferoxamine—Pain—Carboplatin—brain cancer	0.000682	0.00715	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Procarbazine—brain cancer	0.000681	0.00714	CcSEcCtD
Deferoxamine—Blood creatinine increased—Hydroxyurea—brain cancer	0.000653	0.00685	CcSEcCtD
Deferoxamine—Swelling—Carmustine—brain cancer	0.000639	0.0067	CcSEcCtD
Deferoxamine—Body temperature increased—Carboplatin—brain cancer	0.00063	0.00661	CcSEcCtD
Deferoxamine—Hallucination—Procarbazine—brain cancer	0.00062	0.0065	CcSEcCtD
Deferoxamine—Neuropathy—Etoposide—brain cancer	0.000564	0.00591	CcSEcCtD
Deferoxamine—Dysuria—Hydroxyurea—brain cancer	0.000564	0.00591	CcSEcCtD
Deferoxamine—Arrhythmia—Procarbazine—brain cancer	0.000557	0.00584	CcSEcCtD
Deferoxamine—Body temperature increased—Lomustine—brain cancer	0.000551	0.00578	CcSEcCtD
Deferoxamine—Infestation NOS—Hydroxyurea—brain cancer	0.000537	0.00563	CcSEcCtD
Deferoxamine—Infestation—Hydroxyurea—brain cancer	0.000537	0.00563	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Hydroxyurea—brain cancer	0.000527	0.00552	CcSEcCtD
Deferoxamine—Swelling—Etoposide—brain cancer	0.000494	0.00518	CcSEcCtD
Deferoxamine—Leukopenia—Procarbazine—brain cancer	0.000486	0.00509	CcSEcCtD
Deferoxamine—Hallucination—Hydroxyurea—brain cancer	0.00048	0.00503	CcSEcCtD
Deferoxamine—Convulsion—Procarbazine—brain cancer	0.00047	0.00493	CcSEcCtD
Deferoxamine—Arthralgia—Procarbazine—brain cancer	0.000462	0.00484	CcSEcCtD
Deferoxamine—Myalgia—Procarbazine—brain cancer	0.000462	0.00484	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Etoposide—brain cancer	0.00045	0.00472	CcSEcCtD
Deferoxamine—Vomiting—Lomustine—brain cancer	0.000443	0.00465	CcSEcCtD
Deferoxamine—Oedema—Procarbazine—brain cancer	0.000443	0.00464	CcSEcCtD
Deferoxamine—Dysuria—Temozolomide—brain cancer	0.00044	0.00462	CcSEcCtD
Deferoxamine—Infection—Procarbazine—brain cancer	0.00044	0.00461	CcSEcCtD
Deferoxamine—Angiopathy—Hydroxyurea—brain cancer	0.000438	0.00459	CcSEcCtD
Deferoxamine—Shock—Procarbazine—brain cancer	0.000436	0.00457	CcSEcCtD
Deferoxamine—Thrombocytopenia—Procarbazine—brain cancer	0.000434	0.00455	CcSEcCtD
Deferoxamine—Tachycardia—Procarbazine—brain cancer	0.000432	0.00453	CcSEcCtD
Deferoxamine—Renal failure—Carmustine—brain cancer	0.000427	0.00448	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Carmustine—brain cancer	0.000426	0.00446	CcSEcCtD
Deferoxamine—Erythema—Hydroxyurea—brain cancer	0.00042	0.0044	CcSEcCtD
Deferoxamine—Infestation NOS—Temozolomide—brain cancer	0.00042	0.0044	CcSEcCtD
Deferoxamine—Infestation—Temozolomide—brain cancer	0.00042	0.0044	CcSEcCtD
Deferoxamine—Nausea—Lomustine—brain cancer	0.000414	0.00434	CcSEcCtD
Deferoxamine—Hypotension—Procarbazine—brain cancer	0.000414	0.00434	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Temozolomide—brain cancer	0.000412	0.00431	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000403	0.00423	CcSEcCtD
Deferoxamine—Paraesthesia—Procarbazine—brain cancer	0.000398	0.00417	CcSEcCtD
Deferoxamine—Hallucination—Carmustine—brain cancer	0.000388	0.00407	CcSEcCtD
Deferoxamine—Connective tissue disorder—Carmustine—brain cancer	0.000383	0.00402	CcSEcCtD
Deferoxamine—Pain—Procarbazine—brain cancer	0.000379	0.00397	CcSEcCtD
Deferoxamine—Leukopenia—Hydroxyurea—brain cancer	0.000376	0.00394	CcSEcCtD
Deferoxamine—Visual impairment—Carmustine—brain cancer	0.000376	0.00394	CcSEcCtD
Deferoxamine—Hallucination—Temozolomide—brain cancer	0.000375	0.00393	CcSEcCtD
Deferoxamine—Urinary tract disorder—Temozolomide—brain cancer	0.000372	0.0039	CcSEcCtD
Deferoxamine—Connective tissue disorder—Temozolomide—brain cancer	0.00037	0.00388	CcSEcCtD
Deferoxamine—Urethral disorder—Temozolomide—brain cancer	0.000369	0.00387	CcSEcCtD
Deferoxamine—Eye disorder—Carmustine—brain cancer	0.000364	0.00382	CcSEcCtD
Deferoxamine—Convulsion—Hydroxyurea—brain cancer	0.000364	0.00381	CcSEcCtD
Deferoxamine—Visual impairment—Temozolomide—brain cancer	0.000363	0.00381	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Procarbazine—brain cancer	0.000362	0.0038	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000355	0.00372	CcSEcCtD
Deferoxamine—Eye disorder—Temozolomide—brain cancer	0.000352	0.00369	CcSEcCtD
Deferoxamine—Urticaria—Procarbazine—brain cancer	0.000352	0.00369	CcSEcCtD
Deferoxamine—Tinnitus—Temozolomide—brain cancer	0.000351	0.00368	CcSEcCtD
Deferoxamine—Abdominal pain—Procarbazine—brain cancer	0.00035	0.00367	CcSEcCtD
Deferoxamine—Body temperature increased—Procarbazine—brain cancer	0.00035	0.00367	CcSEcCtD
Deferoxamine—XDH—Oxidative Stress—SOD2—brain cancer	0.00035	0.0673	CbGpPWpGaD
Deferoxamine—Arrhythmia—Carmustine—brain cancer	0.000348	0.00365	CcSEcCtD
Deferoxamine—Oedema—Hydroxyurea—brain cancer	0.000343	0.00359	CcSEcCtD
Deferoxamine—Angiopathy—Temozolomide—brain cancer	0.000342	0.00358	CcSEcCtD
Deferoxamine—Infection—Hydroxyurea—brain cancer	0.00034	0.00357	CcSEcCtD
Deferoxamine—Immune system disorder—Temozolomide—brain cancer	0.00034	0.00357	CcSEcCtD
Deferoxamine—Mediastinal disorder—Temozolomide—brain cancer	0.00034	0.00356	CcSEcCtD
Deferoxamine—Erythema—Carmustine—brain cancer	0.000339	0.00356	CcSEcCtD
Deferoxamine—Nervous system disorder—Hydroxyurea—brain cancer	0.000336	0.00352	CcSEcCtD
Deferoxamine—Infestation NOS—Etoposide—brain cancer	0.000336	0.00352	CcSEcCtD
Deferoxamine—Infestation—Etoposide—brain cancer	0.000336	0.00352	CcSEcCtD
Deferoxamine—Thrombocytopenia—Hydroxyurea—brain cancer	0.000336	0.00352	CcSEcCtD
Deferoxamine—Skin disorder—Hydroxyurea—brain cancer	0.000333	0.00349	CcSEcCtD
Deferoxamine—Renal failure—Etoposide—brain cancer	0.00033	0.00346	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Etoposide—brain cancer	0.000329	0.00345	CcSEcCtD
Deferoxamine—Erythema—Temozolomide—brain cancer	0.000328	0.00344	CcSEcCtD
Deferoxamine—Hypersensitivity—Procarbazine—brain cancer	0.000326	0.00342	CcSEcCtD
Deferoxamine—Vision blurred—Carmustine—brain cancer	0.00032	0.00335	CcSEcCtD
Deferoxamine—Pruritus—Procarbazine—brain cancer	0.000313	0.00328	CcSEcCtD
Deferoxamine—Vision blurred—Temozolomide—brain cancer	0.000309	0.00324	CcSEcCtD
Deferoxamine—Dyspnoea—Hydroxyurea—brain cancer	0.000306	0.0032	CcSEcCtD
Deferoxamine—Leukopenia—Carmustine—brain cancer	0.000304	0.00319	CcSEcCtD
Deferoxamine—Diarrhoea—Procarbazine—brain cancer	0.000303	0.00318	CcSEcCtD
Deferoxamine—Angioedema—Temozolomide—brain cancer	0.0003	0.00314	CcSEcCtD
Deferoxamine—Urinary tract disorder—Etoposide—brain cancer	0.000298	0.00312	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000296	0.0031	CcSEcCtD
Deferoxamine—Urethral disorder—Etoposide—brain cancer	0.000296	0.0031	CcSEcCtD
Deferoxamine—Convulsion—Carmustine—brain cancer	0.000294	0.00308	CcSEcCtD
Deferoxamine—Leukopenia—Temozolomide—brain cancer	0.000294	0.00308	CcSEcCtD
Deferoxamine—Pain—Hydroxyurea—brain cancer	0.000293	0.00307	CcSEcCtD
Deferoxamine—Dizziness—Procarbazine—brain cancer	0.000293	0.00307	CcSEcCtD
Deferoxamine—Myalgia—Carmustine—brain cancer	0.000289	0.00303	CcSEcCtD
Deferoxamine—Convulsion—Temozolomide—brain cancer	0.000284	0.00298	CcSEcCtD
Deferoxamine—Eye disorder—Etoposide—brain cancer	0.000282	0.00295	CcSEcCtD
Deferoxamine—Vomiting—Procarbazine—brain cancer	0.000282	0.00295	CcSEcCtD
Deferoxamine—Arthralgia—Temozolomide—brain cancer	0.000279	0.00293	CcSEcCtD
Deferoxamine—Myalgia—Temozolomide—brain cancer	0.000279	0.00293	CcSEcCtD
Deferoxamine—Headache—Procarbazine—brain cancer	0.000277	0.00291	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000277	0.00291	CcSEcCtD
Deferoxamine—Oedema—Carmustine—brain cancer	0.000277	0.0029	CcSEcCtD
Deferoxamine—Infection—Carmustine—brain cancer	0.000275	0.00289	CcSEcCtD
Deferoxamine—Angiopathy—Etoposide—brain cancer	0.000274	0.00287	CcSEcCtD
Deferoxamine—Immune system disorder—Etoposide—brain cancer	0.000272	0.00286	CcSEcCtD
Deferoxamine—Mediastinal disorder—Etoposide—brain cancer	0.000272	0.00285	CcSEcCtD
Deferoxamine—Thrombocytopenia—Carmustine—brain cancer	0.000271	0.00284	CcSEcCtD
Deferoxamine—Body temperature increased—Hydroxyurea—brain cancer	0.000271	0.00284	CcSEcCtD
Deferoxamine—Tachycardia—Carmustine—brain cancer	0.00027	0.00283	CcSEcCtD
Deferoxamine—Anaphylactic shock—Temozolomide—brain cancer	0.000268	0.00281	CcSEcCtD
Deferoxamine—Oedema—Temozolomide—brain cancer	0.000268	0.00281	CcSEcCtD
Deferoxamine—Infection—Temozolomide—brain cancer	0.000266	0.00279	CcSEcCtD
Deferoxamine—Nausea—Procarbazine—brain cancer	0.000263	0.00276	CcSEcCtD
Deferoxamine—Nervous system disorder—Temozolomide—brain cancer	0.000263	0.00275	CcSEcCtD
Deferoxamine—Thrombocytopenia—Temozolomide—brain cancer	0.000262	0.00275	CcSEcCtD
Deferoxamine—Skin disorder—Temozolomide—brain cancer	0.00026	0.00273	CcSEcCtD
Deferoxamine—Hypotension—Carmustine—brain cancer	0.000259	0.00271	CcSEcCtD
Deferoxamine—Hypersensitivity—Hydroxyurea—brain cancer	0.000253	0.00265	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Carmustine—brain cancer	0.000252	0.00265	CcSEcCtD
Deferoxamine—Muscle spasms—Etoposide—brain cancer	0.000252	0.00265	CcSEcCtD
Deferoxamine—Paraesthesia—Carmustine—brain cancer	0.000249	0.00261	CcSEcCtD
Deferoxamine—Dyspnoea—Carmustine—brain cancer	0.000247	0.00259	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000244	0.00256	CcSEcCtD
Deferoxamine—Paraesthesia—Temozolomide—brain cancer	0.00024	0.00252	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Carmustine—brain cancer	0.000239	0.00251	CcSEcCtD
Deferoxamine—Dyspnoea—Temozolomide—brain cancer	0.000239	0.0025	CcSEcCtD
Deferoxamine—Pain—Carmustine—brain cancer	0.000237	0.00248	CcSEcCtD
Deferoxamine—Leukopenia—Etoposide—brain cancer	0.000235	0.00246	CcSEcCtD
Deferoxamine—Diarrhoea—Hydroxyurea—brain cancer	0.000234	0.00246	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000231	0.00242	CcSEcCtD
Deferoxamine—Pain—Temozolomide—brain cancer	0.000229	0.0024	CcSEcCtD
Deferoxamine—Convulsion—Etoposide—brain cancer	0.000227	0.00238	CcSEcCtD
Deferoxamine—Dizziness—Hydroxyurea—brain cancer	0.000227	0.00238	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Carmustine—brain cancer	0.000227	0.00238	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000222	0.00233	CcSEcCtD
Deferoxamine—Abdominal pain—Carmustine—brain cancer	0.000219	0.0023	CcSEcCtD
Deferoxamine—Body temperature increased—Carmustine—brain cancer	0.000219	0.0023	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Temozolomide—brain cancer	0.000219	0.0023	CcSEcCtD
Deferoxamine—Vomiting—Hydroxyurea—brain cancer	0.000218	0.00228	CcSEcCtD
Deferoxamine—Headache—Hydroxyurea—brain cancer	0.000215	0.00225	CcSEcCtD
Deferoxamine—Anaphylactic shock—Etoposide—brain cancer	0.000214	0.00225	CcSEcCtD
Deferoxamine—Infection—Etoposide—brain cancer	0.000213	0.00223	CcSEcCtD
Deferoxamine—Urticaria—Temozolomide—brain cancer	0.000213	0.00223	CcSEcCtD
Deferoxamine—Body temperature increased—Temozolomide—brain cancer	0.000212	0.00222	CcSEcCtD
Deferoxamine—Abdominal pain—Temozolomide—brain cancer	0.000212	0.00222	CcSEcCtD
Deferoxamine—Thrombocytopenia—Etoposide—brain cancer	0.00021	0.0022	CcSEcCtD
Deferoxamine—Tachycardia—Etoposide—brain cancer	0.000209	0.00219	CcSEcCtD
Deferoxamine—Skin disorder—Etoposide—brain cancer	0.000208	0.00218	CcSEcCtD
Deferoxamine—Hypersensitivity—Carmustine—brain cancer	0.000204	0.00214	CcSEcCtD
Deferoxamine—Nausea—Hydroxyurea—brain cancer	0.000204	0.00213	CcSEcCtD
Deferoxamine—Hypotension—Etoposide—brain cancer	0.0002	0.0021	CcSEcCtD
Deferoxamine—Hypersensitivity—Temozolomide—brain cancer	0.000197	0.00207	CcSEcCtD
Deferoxamine—Paraesthesia—Etoposide—brain cancer	0.000192	0.00202	CcSEcCtD
Deferoxamine—Dyspnoea—Etoposide—brain cancer	0.000191	0.002	CcSEcCtD
Deferoxamine—Diarrhoea—Carmustine—brain cancer	0.00019	0.00199	CcSEcCtD
Deferoxamine—Pruritus—Temozolomide—brain cancer	0.000189	0.00199	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Etoposide—brain cancer	0.000185	0.00194	CcSEcCtD
Deferoxamine—Dizziness—Carmustine—brain cancer	0.000183	0.00192	CcSEcCtD
Deferoxamine—Pain—Etoposide—brain cancer	0.000183	0.00192	CcSEcCtD
Deferoxamine—Diarrhoea—Temozolomide—brain cancer	0.000183	0.00192	CcSEcCtD
Deferoxamine—Dizziness—Temozolomide—brain cancer	0.000177	0.00186	CcSEcCtD
Deferoxamine—Vomiting—Carmustine—brain cancer	0.000176	0.00185	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Etoposide—brain cancer	0.000175	0.00184	CcSEcCtD
Deferoxamine—Headache—Carmustine—brain cancer	0.000174	0.00182	CcSEcCtD
Deferoxamine—Vomiting—Temozolomide—brain cancer	0.00017	0.00178	CcSEcCtD
Deferoxamine—Urticaria—Etoposide—brain cancer	0.00017	0.00178	CcSEcCtD
Deferoxamine—Body temperature increased—Etoposide—brain cancer	0.000169	0.00178	CcSEcCtD
Deferoxamine—Abdominal pain—Etoposide—brain cancer	0.000169	0.00178	CcSEcCtD
Deferoxamine—Headache—Temozolomide—brain cancer	0.000168	0.00176	CcSEcCtD
Deferoxamine—Nausea—Carmustine—brain cancer	0.000165	0.00173	CcSEcCtD
Deferoxamine—Nausea—Temozolomide—brain cancer	0.000159	0.00167	CcSEcCtD
Deferoxamine—Hypersensitivity—Etoposide—brain cancer	0.000158	0.00165	CcSEcCtD
Deferoxamine—Pruritus—Etoposide—brain cancer	0.000152	0.00159	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—SOD2—brain cancer	0.000148	0.0284	CbGpPWpGaD
Deferoxamine—Diarrhoea—Etoposide—brain cancer	0.000147	0.00154	CcSEcCtD
Deferoxamine—Dizziness—Etoposide—brain cancer	0.000142	0.00149	CcSEcCtD
Deferoxamine—Vomiting—Etoposide—brain cancer	0.000136	0.00143	CcSEcCtD
Deferoxamine—Headache—Etoposide—brain cancer	0.000134	0.00141	CcSEcCtD
Deferoxamine—Nausea—Etoposide—brain cancer	0.000127	0.00133	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—RELA—brain cancer	8.55e-05	0.0164	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP2C9—brain cancer	4.13e-05	0.00794	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—BSG—brain cancer	3.51e-05	0.00675	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—IDH1—brain cancer	3.02e-05	0.00581	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ENO2—brain cancer	2.39e-05	0.00459	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CG—brain cancer	1.09e-05	0.00211	CbGpPWpGaD
